<DOC>
	<DOCNO>NCT00000833</DOCNO>
	<brief_summary>To compare safety , toxicity , tolerance two dos ribavirin combination didanosine ( ddI ) HIV-infected child . To determine toxicity ddI/ribavirin compare expect toxicity ddI monotherapy . To determine effect concurrent ribavirin pharmacokinetics ddI . To determine dosage ribavirin would suitable Phase II/III evaluation ddI/ribavirin . Ribavirin , broad spectrum antiviral agent , may enhance antiretroviral activity didanosine ( ddI ) without concomitant increase toxicity . Ribavirin alters intracellular metabolism ddI , enhance antiretroviral activity active form ddI .</brief_summary>
	<brief_title>A Phase I Study Combination Therapy With Didanosine ( ddI ) Ribavirin HIV-Infected Children .</brief_title>
	<detailed_description>Ribavirin , broad spectrum antiviral agent , may enhance antiretroviral activity didanosine ( ddI ) without concomitant increase toxicity . Ribavirin alters intracellular metabolism ddI , enhance antiretroviral activity active form ddI . Patients divide two cohort . Subjects stratify age 3 month &lt; 24 month &gt; = 24 month 12 year . Fifty % patient age group assign cohort . Cohort 1 receives ddI monotherapy 4 week , follow combination ddl/ribavirin therapy additional 20 week . Cohort 2 receives combination ddI/ribavirin 24 week . In cohort , study medication stop , patient treat prescription antiretrovirals 4 week . [ AS PER AMENDMENT 7/2/96 : Note : In cohort 10 subject least 2 5 child old half cohort ICD p24 antigen entry . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : Acetaminophen 72 hour . Immunoglobulin . Corticosteroids . Erythropoietin . GCSF GMCSF . Ethionamide isoniazid TB alternative available . Immunizations accord current recommendation . Patients must : HIV infection . Immunologic abnormality clinical symptom detail Disease Status field . No active AIDSdefining opportunistic infection malignancy , progressive encephalopathy attributable HIV chronic persistent diarrhea . Consent parent guardian . PER AMENDMENT 7/2/96 : At least 2 5 child old half cohort must ICD p24 antigen concentration &gt; = 70 pg/ml screening . Prior Medication : Allowed : Up 6 week prior immunomodulator therapy . Maternal immunomodulator antiretroviral therapy , include pregnancy . Prior corticosteroid intravenous immunoglobulin . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current grade 3 bad neuropathy/lower motor neuropathy . Clinical laboratory grade 3 bad toxicity . Active serious bacterial infection . Concurrent Medication : Excluded : Chemotherapy active malignancy . Antiretrovirals study drug . Immunomodulators unless specifically allow . Patients follow prior condition exclude : History grade 3 bad neuropathy/lower motor neuropathy . Prior Medication : Excluded : Prior ddI oral ribavirin . Aerosolized ribavirin within 6 week prior study entry . Antiretroviral immunomodulator therapy ( corticosteroid IVIG ) within 1 week prior blood draw study entry . Ongoing drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>